Payment overview · 2025
General Payments
$175.90
2 reported records · 2 companies
Healthcare provider profile · identity verified
Deborah Suzanne Marsden
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SAYRE, PA · NPI 1831754357
Verified facts
What the public records show
CMS Open Payments records show Deborah Suzanne Marsden received $175.90 in general payments during 2025 across 2 reported records.
Dexcom, Inc. accounted for 66.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $117.56 | 66.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.34 | 33.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $175.90 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $117.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
34 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 152 |
| Metformin Hcl | Metformin Hcl | 392 | 115 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 367 | 129 |
| Ozempic | Semaglutide | 340 | 76 |
| Mounjaro | Tirzepatide | 264 | 52 |
| Jardiance | Empagliflozin | 231 | 60 |
| Metformin Hcl Er | Metformin Hcl | 215 | 61 |
| Glimepiride | Glimepiride | 209 | 59 |
| Farxiga | Dapagliflozin Propanediol | 202 | 42 |
| Trulicity | Dulaglutide | 191 | 45 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 177 | 55 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 162 | 52 |
| Novolog Flexpen | Insulin Aspart | 160 | 63 |
| Gabapentin | Gabapentin | 146 | 40 |
| Glipizide Er | Glipizide | 124 | 38 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 118 | 39 |
| Glipizide | Glipizide | 105 | 29 |
| Novolog | Insulin Aspart | 99 | 33 |
| Liothyronine Sodium | Liothyronine Sodium | 96 | 30 |
| Humalog Kwikpen U-100 | Insulin Lispro | 94 | 29 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 85 | 33 |
| Synthroid | Levothyroxine Sodium | 81 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 78 | 23 |
| Januvia | Sitagliptin Phosphate | 76 | 21 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 74 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 26 |
| Tresiba Flextouch U-100 | Insulin Degludec | 70 | 21 |
| Lisinopril | Lisinopril | 64 | 20 |
| Insulin Lispro | Insulin Lispro | 63 | 19 |
| Droplet Pen Needle | Pen Needle, Diabetic | 57 | 22 |
| Methimazole | Methimazole | 51 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | 21 |
| Simvastatin | Simvastatin | 45 | 13 |
| Admelog Solostar | Insulin Lispro | 43 | 13 |
| Humalog | Insulin Lispro | 36 | 15 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Prolia | Denosumab | 34 | 23 |
| Repaglinide | Repaglinide | 34 | suppressed |
| Levemir Flexpen | Insulin Detemir | 33 | 14 |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Invokana | Canagliflozin | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 18 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Admelog | Insulin Lispro | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | 12 |
| Victoza 3-Pak | Liraglutide | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 15 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $175.90 · 2 records | Dexcom, Inc. | Dexcom G6 Transmitter, EVENITY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error